Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Completed NCT03568461

Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma

Conditions: Follicular Lymphoma

Sex: All

Ages: 18 Years – 100 Years

Healthy volunteers: No

Phase: PHASE2

Enrollment: 98

Sponsor: Novartis Pharmaceuticals

Location: City of Hope National Medical Center Duarte California

Summary

This is a multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.

Eligibility Criteria

Inclusion Criteria: * Refractory or relapsed Follicular Lymphoma (Grade 1, 2, 3A) * Radiographically measurable disease at screening Exclusion Criteria: * Evidence of histologic transformation * Follicular Lymphoma Grade 3B * Prior anti-CD19 therapy * Prior gene therapy * Prior adoptive T cell therapy * Prior allogeneic hematopoietic stem cell transplant * Active CNS involvement by malignancy Other protocol-defined Inclusion/Exclusion criteria may apply.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT03568461). StuddyBuddy aggregates publicly available trial information.